BioSpace News Archive

AEON Biopharma, Inc. (“AEON” or the “Company”) announced today that it will host a key opinion leader (KOL) webinar on the past, present, and potential future treatments for migraine using botulinum toxin on Friday, February 24, 2023 at 11:00 a.m. Eastern Time.

OrthoPediatrics Corp., a company focused exclusively on advancing the field of pediatric orthopedics, announced that the Company is scheduled to release its fourth quarter and full year 2022 financial results on Tuesday, February 28, 2023, after the market closes.

Vaxart, Inc. (NASDAQ: VXRT) today announced that it has dosed the first subject in the Phase 2 clinical trial of its oral tablet bivalent norovirus candidate.

Neurona Therapeutics announced that the U.S. Food and Drug Administration (FDA) has cleared an amendment to Neurona’s ongoing Phase I/II clinical trial of NRTX-1001 in people with drug-resistant mesial temporal lobe epilepsy (MTLE) enabling expansion of enrollment to include adults who have dominant-lobe disease, as well as those whose disease is focused in the non-dominant lobe.

Cidara Therapeutics, Inc., a biotechnology company developing long-acting therapeutics designed to help improve the standard of care for patients facing serious diseases, announced that it has received formal notice from The Nasdaq Stock Market, LLC, stating that the Company has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550.

Propella Therapeutics, Inc. (“Propella”), a private, clinical-stage biopharmaceutical company developing best-in-class oncology therapeutics, today announced that Dr. Jose Avitia of the New Mexico Cancer Center will present updated data from the Company’s ongoing Phase 1/2a study of PRL-02 for the treatment of advanced prostate cancer on Thursday Feb 16 from 11:30AM to 1:00PM PST at the 2023 ASCO Genitourinary (GU) Cancers Symposium.

Poseida Therapeutics, Inc. (Nasdaq: PSTX) today announced that the Company’s Chief Executive Officer, Mark Gergen, will participate in a fireside chat at the H.C. Wainwright Cell Therapy Virtual Conference on February 28, 2023, at 11:00 AM ET.

Sosei Group Corporation, the world leader in G protein-coupled receptor focused structure-based drug design and development, provides an update on operational activities and reports its consolidated results for the 12 months ended 31 December 2022.

(“Relief Therapeutics” or the “Company”), a biopharmaceutical company developing and commercializing novel, patent-protected products in select specialty and rare diseases, announced today the first three patients have been enrolled in a proof-of-concept, investigator-initiated study to evaluate RLF-TD011 as a treatment for epidermolysis bullosa (EB).

FSD Pharma Inc., a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory, and metabolic disorders, announced the launch of a new research and development program focused on unmet medical needs for alcohol misuse.